Published August 9, 2016 | Version v1
Journal article

HDAC 1 and 6 modulate cell invasion and migration in clear cell renal cell carcinoma

  • 1. Department of Pharmacology and Therapeutics, Roswell Park Cancer Institute, Buffalo, NY (United States)
  • 2. Genitourinary Program, Roswell Park Cancer Institute, Buffalo, NY (United States)
  • 3. Department of Cancer Pathology and Prevention, Roswell Park Cancer Institute, Buffalo, NY (United States)
  • 4. Department of Medicine and Experimental Oncology, University of Turin, Turin (Italy)
  • 5. Department of Biostatistics & Bioinformatics, Roswell Park Cancer Institute, Buffalo, NY (United States)
  • 6. Genitourinary Program, Indiana University- Simon Cancer Center, Indianapolis, IN (United States)
  • 7. Center for Integrative Medicine and Innovative Science-Universidad Andres Bello, Santiago (Chile)
  • 8. Department of Cancer Genetics, Roswell Park Cancer Institute, Buffalo, NY (United States)

Description

Class I histone deacetylases (HDACs) have been reported to be overexpressed in clear cell renal cell carcinoma (ccRCC), whereas the expression of class II HDACs is unknown. Four isogenic cell lines C2/C2VHL and 786-O/786-OVHL with differential VHL expression are used in our studies. Cobalt chloride is used to mimic hypoxia in vitro. HIF-2α knockdowns in C2 and 786-O cells is used to evaluate the effect on HDAC 1 expression and activity. Invasion and migration assays are used to investigate the role of HDAC 1 and HDAC 6 expression in ccRCC cells. Comparisons are made between experimental groups using the paired T-test, the two-sample Student's T-test or one-way ANOVA, as appropriate. ccRCC and the TCGA dataset are used to observe the clinical correlation between HDAC 1 and HDAC 6 overexpression and overall and progression free survival. Our analysis of tumor and matched non-tumor tissues from radical nephrectomies showed overexpression of class I and II HDACs (HDAC6 only in a subset of patients). In vitro, both HDAC1 and HDAC6 over-expression increased cell invasion and motility, respectively, in ccRCC cells. HDAC1 regulated invasiveness by increasing matrix metalloproteinase (MMP) expression. Furthermore, hypoxia stimulation in VHL-reconstituted cell lines increased HIF isoforms and HDAC1 expression. Presence of hypoxia response elements in the HDAC1 promoter along with chromatin immunoprecipitation data suggests that HIF-2α is a transcriptional regulator of HDAC1 gene. Conversely, HDAC6 and estrogen receptor alpha (ERα) were co-localized in cytoplasm of ccRCC cells and HDAC6 enhanced cell motility by decreasing acetylated α-tubulin expression, and this biological effect was attenuated by either biochemical or pharmacological inhibition. Finally, analysis of human ccRCC specimens revealed positive correlation between HIF isoforms and HDAC. HDAC1 mRNA upregulation was associated with worse overall survival in the TCGA dataset. Taking together, these results suggest that HDAC1 and HDAC6 may play a role in ccRCC biology and could represent rational therapeutic targets. The online version of this article (doi:10.1186/s12885-016-2604-7) contains supplementary material, which is available to authorized users

Availability note (English)

Available from http://dx.doi.org/10.1186/s12885-016-2604-7; Available from http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4977667

Additional details

Publishing Information

Journal Title
BMC cancer (Online)
Journal Volume
16
Journal Page Range
vp.
ISSN
1471-2407

INIS

Country of Publication
United Kingdom
Country of Input or Organization
International Atomic Energy Agency (IAEA)
INIS RN
47088273
Subject category
S62: RADIOLOGY AND NUCLEAR MEDICINE;
Descriptors DEI
ANOXIA; AUGMENTATION; CARCINOMAS; COBALT CHLORIDES; IN VITRO; KIDNEYS; MIGRATION
Descriptors DEC
BODY; CHLORIDES; CHLORINE COMPOUNDS; COBALT COMPOUNDS; COBALT HALIDES; DISEASES; HALIDES; HALOGEN COMPOUNDS; NEOPLASMS; ORGANS; TRANSITION ELEMENT COMPOUNDS

Optional Information

Copyright
Copyright (c) The Author(s). 2016
Notes
PMCID: PMC4977667; PUBLISHER-ID: 2604; OAI: oai:pubmedcentral.nih.gov:4977667